Drug treatment means better, less costly care for children with sickle cell disease

September 11, 2013, Johns Hopkins University School of Medicine

The benefits of hydroxyurea treatment in people with sickle cell disease are well known—fewer painful episodes, fewer blood transfusions and fewer hospitalizations. Now new research from the Johns Hopkins Children's Center and other institutions reveals that by preventing such complications, the drug can also considerably lower the overall cost of medical care in children with this condition.

The cost-benefit analysis, described online Sept. 2 in the journal Pediatrics and believed to be the first of its kind in , showed that whose standard care was augmented with daily hydroxyurea incurred, on average, $3,000 less in per year, compared with children who got standard therapy plus placebo.

"In addition to alleviating the human suffering in sickle cell disease, we found that hydroxyurea had the pleasant 'side effect' of substantially lowering the cost of care among children treated with it," says study investigator James Casella, M.D., director of pediatric at the Johns Hopkins Children's Center. "Our main goal is to find better treatments, but in a time when we are trying to curb while improving , this is really welcome news."

Although proven valuable in therapy of sickle-cell disease, hydroxyurea remains woefully underused in the treatment of people with this condition, the investigators say. The new findings, the research team says, should encourage more physicians to consider adding hydroxyurea to their patients' therapeutic regimens.

"Our analysis specifically demonstrates an added benefit to the use of hydroxyurea for treatment of sickle cell disease related to the drug's impact on the cost of medical care and should be another factor in support of more widespread use of the drug in both children and adults," says the study's lead investigator Winfred Wang, M.D., of the Hematology Department at St. Jude Children's Research Hospital.

Sickle cell disease, a that affects people of African, Middle Eastern, Mediterranean and Hispanic descent, is marked by abnormally C-shaped or "sickled" red blood cells—the cells that store and distribute oxygen throughout the body. Because of their abnormal shape, the cells periodically clump inside blood vessels, blocking circulation, which can lead to severe anemia, drive up infection and stroke risk and cause episodes of extreme pain.

Hydroxyurea—the only FDA-approved drug to treat the excruciating pain crises of sickle cell disease—works by boosting the levels of a type of hemoglobin that makes red blood cells less likely to bend and clump. Although the drug's beneficial effects on alleviating sickle cell pain were first demonstrated at Johns Hopkins in the mid-1990s, the compound was first synthesized in the late 1800s and has been used mainly in the treatment of certain blood cancers.

In the current study, investigators reviewed the number and cost of hospitalizations among 167 sickle cell patients, ages 1 to 3, treated at three pediatric hospitals between 2003 and 2009. Half of the patients received hydroxyurea in addition to their standard care of pain medication and periodic blood transfusions, while the remainder received standard care plus placebo.

Children treated with hydroxyurea were hospitalized 232 times, compared with 324 hospitalizations among those treated without it. The average cost of hospitalization for children who received hydroxyurea was $9,450 compared with $13,716 among those who received placebo instead. Outpatient treatment was more expensive among children who received hydroxyurea ($1,622 per year), compared with those treated without it ($246), but the higher outpatient cost was offset by fewer hospitalizations and fewer complications. The average cost of all care, including inpatient and outpatient, among children treated with hydroxyurea was $11,072, compared with $13,962 for those treated with placebo.

The lower cost associated with hydroxyurea therapy stems from the compound's ability to prevent or reduce the occurrence of pain crises and serious respiratory complications that require blood transfusions and other treatments, the researchers say. An earlier study by the same group found that children treated with had fewer such complications than children not receiving the treatment.

About 100,000 people have sickle cell disease in the United States.

Explore further: Drug reduces hospitalizations and cost of treating young children with sickle cell anemia

Related Stories

Drug reduces hospitalizations and cost of treating young children with sickle cell anemia

September 2, 2013
A drug proven effective for treatment of adults and children with sickle cell anemia reduced hospitalizations and cut annual estimated medical costs by 21 percent for affected infants and toddlers, according to an analysis ...

Sickle cell anemia drug safe and effective for infants and toddlers, adds treatment option

May 12, 2011
New research shows a drug commonly used to treat sickle cell anemia in adults reduces bouts of acute pain and a pneumonia-like illness, cuts hospitalization time and eases other symptoms of the disease in young patients. ...

Researchers reveal potential treatment for sickle cell disease

November 2, 2011
A University of Michigan Health System laboratory study reveals a key trigger for producing normal red blood cells that could lead to a new treatment for those with sickle cell disease.

Recommended for you

Baby brains help infants figure it out before they try it out

January 17, 2018
Babies often amaze their parents when they seemingly learn new skills overnight—how to walk, for example. But their brains were probably prepping for those tasks long before their first steps occurred, according to researchers.

NeuroNext biomarker study explores natural history of infantile-onset SMA

January 9, 2018
Research led by The Ohio State University Wexner Medical Center to define the natural history of infantile-onset spinal muscular atrophy (SMA) has been "critical" to accelerate the development of effective therapies and hasten ...

No link between childhood lead levels, later criminality

December 27, 2017
(HealthDay)— Exposure to higher levels of lead during early childhood can affect neurological development—but does that mean affected kids are doomed to delinquency?

Early puberty in girls may take mental health toll

December 26, 2017
(HealthDay)—A girl who gets her first menstrual period early in life—possibly as young as 7—has a greater risk for developing depression and antisocial behaviors that last at least into her 20s, a new study suggests.

Technology not taking over children's lives despite screen-time increase

December 21, 2017
With children spending increasing amounts of time on screen-based devices, there is a common perception that technology is taking over their lives, to the detriment and exclusion of other activities. However, new Oxford University ...

Higher blood sugar in early pregnancy raises baby's heart-defect risk

December 15, 2017
Higher blood sugar early in pregnancy raises the baby's risk of a congenital heart defect, even among mothers who do not have diabetes, according to a study led by researchers at the Stanford University School of Medicine.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.